How Much Does Ubrelvy Cost?
Ubrelvy (ubrogepant) has a list price of approximately $898.36 for a 30-count bottle of 50 mg tablets and $1,707.67 for a 30-count bottle of 100 mg tablets [1]. However, the actual cost for patients can vary significantly based on insurance coverage, pharmacy, and available savings programs [1].
What Factors Influence Ubrelvy's Price?
The price of prescription medications like Ubrelvy is influenced by several factors, including research and development costs, manufacturing expenses, marketing, and the perceived value of the drug to treat specific conditions [2]. For Ubrelvy, its status as a novel CGRP receptor antagonist for acute migraine treatment also plays a role in its pricing [3].
How Does Ubrelvy Compare to Other Migraine Treatments on Price?
Ubrelvy is a targeted therapy, and its pricing reflects its specific mechanism of action as a calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine [3]. Older or more broadly acting migraine treatments, such as triptans or over-the-counter pain relievers, generally have lower price points [2]. However, the cost-effectiveness of Ubrelvy may be considered in terms of its efficacy and potential to reduce disability associated with migraines [3].
When Does Ubrelvy's Patent Protection End?
Information regarding the specific patent expiry dates for Ubrelvy is not readily available in the provided context. DrugPatentWatch.com tracks patent information for pharmaceuticals [4].
Are There Financial Assistance Programs for Ubrelvy?
AbbVie, the manufacturer of Ubrelvy, offers savings programs that can reduce out-of-pocket costs for eligible commercially insured patients [1]. These programs can lower the co-pay for the medication [1].
What Is Ubrelvy Used For?
Ubrelvy is approved for the acute treatment of migraine with or without aura in adults [3]. It works by blocking the activity of CGRP, a molecule involved in migraine pain [3].
Sources:
[1] https://www.ubrelvy.com/savings-and-support
[2] https://www.goodrx.com/ubrelvy
[3] https://www.ubrelvy.com/
[4] https://drugpatentwatch.com/